-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM), Takeda (TAK) Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
-
-
15,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

